DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 193 filers reported holding DENALI THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $6,556,000 | +13.7% | 376,364 | 0.0% | 0.01% | 0.0% |
| Q3 2019 | $5,766,000 | -26.2% | 376,364 | 0.0% | 0.01% | -25.0% |
| Q2 2019 | $7,813,000 | -73.5% | 376,364 | -70.3% | 0.01% | -73.9% |
| Q1 2019 | $29,467,000 | +2.1% | 1,269,036 | -9.2% | 0.05% | -9.8% |
| Q4 2018 | $28,859,000 | -52.4% | 1,396,885 | -49.9% | 0.05% | -43.3% |
| Q3 2018 | $60,589,000 | -12.4% | 2,786,979 | -38.6% | 0.09% | -13.5% |
| Q2 2018 | $69,184,000 | -16.0% | 4,536,715 | +8.4% | 0.10% | -54.0% |
| Q1 2018 | $82,402,000 | +25.9% | 4,184,982 | 0.0% | 0.23% | +24.2% |
| Q4 2017 | $65,453,000 | – | 4,184,982 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,460,732 | $240,012,000 | 28.78% |
| Casdin Capital, LLC | 1,500,000 | $48,255,000 | 2.16% |
| Flagship Pioneering Inc. | 2,619,968 | $84,284,000 | 1.98% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 38,000 | $8,192,000 | 1.85% |
| Yiheng Capital Management, L.P. | 1,014,684 | $32,642,000 | 1.49% |
| SECTORAL ASSET MANAGEMENT INC | 207,100 | $6,662,000 | 1.18% |
| Artal Group S.A. | 600,000 | $19,302,000 | 0.81% |
| GILDER GAGNON HOWE & CO LLC | 2,619,217 | $84,260,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $172,736,397 | 0.73% |
| BRANDYWINE MANAGERS, LLC | 9,601 | $309,000 | 0.53% |